Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
28 feb 2014 - 07:00
Statutaire naam
Galapagos NV
Titel
Galapagos provides status update for GSK2586184 in GSK’s psoriasis, lupus, and ulcerative colitis clinical studies
Bericht
Mechelen, Belgium; 28 February 2014 – Galapagos NV (Euronext: GLPG) announced today that GSK has updated the development status for GSK2586184, involving three clinical studies in psoriasis, lupus, and ulcerative colitis.
GSK2586184 is a selective JAK1 inhibitor which was discovered and developed within Galapagos’ inflammation alliance with GSK. GSK in-licensed the molecule in February 2012, gaining worldwide rights to further development and commercialization. Galapagos is eligible, without further financial investment from Galapagos, to receive from GSK up to €34M in additional milestones, plus up to double-digit royalties on global commercial sales of all therapeutic indications of GSK2586184.
Datum laatste update: 08 januari 2026